KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Receivables - Other (2020 - 2023)

Historic Receivables - Other for Pfizer (PFE) over the last 8 years, with Q2 2023 value amounting to $57.0 million.

  • Pfizer's Receivables - Other fell 5714.29% to $57.0 million in Q2 2023 from the same period last year, while for Apr 2023 it was $57.0 million, marking a year-over-year decrease of 5714.29%. This contributed to the annual value of $53.0 million for FY2021, which is 8678.3% down from last year.
  • Per Pfizer's latest filing, its Receivables - Other stood at $57.0 million for Q2 2023, which was down 5714.29% from $167.0 million recorded in Q4 2022.
  • Pfizer's Receivables - Other's 5-year high stood at $871.0 million during Q2 2021, with a 5-year trough of $53.0 million in Q4 2021.
  • For the 4-year period, Pfizer's Receivables - Other averaged around $287.2 million, with its median value being $197.0 million (2021).
  • Its Receivables - Other has fluctuated over the past 5 years, first plummeted by 8678.3% in 2021, then crashed by 1522.84% in 2022.
  • Pfizer's Receivables - Other (Quarter) stood at $401.0 million in 2020, then tumbled by 86.78% to $53.0 million in 2021, then skyrocketed by 215.09% to $167.0 million in 2022, then crashed by 65.87% to $57.0 million in 2023.
  • Its Receivables - Other was $57.0 million in Q2 2023, compared to $167.0 million in Q4 2022 and $272.0 million in Q3 2022.